Since PTEN loss or PI3K pathway activation is one of the most frequently altered pathways in human cancers, our work may shed light on how to successfully combine anti-PI3K targeted therapy with ICT for broad and long-lasting therapeutic effects on other cancer types with PTEN loss or PI3K activation. The gene discussed is PTEN; the disease is cancer.